Alvita Pharma Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 19-12-2024
- Paid Up Capital ₹ 9.00 Cr
as on 19-12-2024
- Company Age 14 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.00 Cr
as on 19-12-2024
- Satisfied Charges ₹ 59.65 Cr
as on 19-12-2024
- Revenue -2.91%
(FY 2022)
- Profit 6.82%
(FY 2022)
- Ebitda 18.28%
(FY 2022)
- Net Worth 25.68%
(FY 2022)
- Total Assets 22.11%
(FY 2022)
About Alvita Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 9.00 Cr.
The company currently has active open charges totaling ₹6.00 Cr. The company has closed loans amounting to ₹59.65 Cr, as per Ministry of Corporate Affairs (MCA) records.
Surendra Lohia, Manoj Vora, and Sajan Unnithan serve as directors at the Company.
- CIN/LLPIN
U24230GJ2010PTC059305
- Company No.
059305
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jan 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Alvita Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surendra Lohia  | Director | 02-Feb-2015 | Current |
| Manoj Vora | Director | 14-Jul-2010 | Current |
| Sajan Unnithan | Director | 16-Sep-2010 | Current |
Financial Performance of Alvita Pharma.
Alvita Pharma Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 2.91% decrease. The company also saw a slight improvement in profitability, with a 6.82% increase in profit. The company's net worth Soared by an impressive increase of 25.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alvita Pharma?
In 2022, Alvita Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 03 Jan 2013 | ₹6.00 Cr | Open |
Hdfc Bank Limited Creation Date: 10 Dec 2020 | ₹30.51 Cr | Satisfied |
Indian Bank Creation Date: 26 Jul 2017 | ₹27.70 Cr | Satisfied |
How Many Employees Work at Alvita Pharma?
Alvita Pharma has a workforce of 54 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alvita Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alvita Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
